A Coruna

• Feasibility study of Neo-adjuvant (before surgery) versus Adjuvant (after surgery) chemotherapy in Upper Tract Urothelial Carcinoma Under evaluation
  2024-514991-41-01 4 Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cel
• MK-0616-013 Not authorised
  2022-502777-42-00 5 Hypercholesterolemia
• Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Not authorised
  2022-503126-12-00 5 Hypoparathyroidism
• Evaluation of the safety and efficacy of the drug AL8326 in the post-first treatment of small cell lung cancer. Not authorised
  2023-509067-24-00 4 Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment wi
• A study to find how well budoprutug (TNT119) works and how safe it is in participants with immune thrombocytopenia Not authorised
  2024-519745-30-00 9 Immune Thrombocytopenia (ITP)
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Phase 1/2 Study of BLU-451 in certain advanced cancers Pending
  2022-502527-21-00 7 Advanced cancers with EGFR Exon20 insertions mutations
• Sarilumab efficacy and safety in adults with early polymyalgia rheumatica Pending
  2024-511296-15-00 5 Musculoskeletal diseases
• Extension Study of ACT-EARLY Pending
  2024-513676-18-00 5 Transthyretin Amyloidosis
• Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial) Pending
  2024-515240-24-00 4 Locally advanced rectal cancer
• A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient … Pending
  2024-517621-54-00 5 High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br … Pending
  2024-518026-32-00 5 Invasive Breast Cancer
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf … Pending
  2025-521230-29-00 5 Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Der
• A Study to Investigate Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis (KATALYST-AV) Pending
  2025-522176-86-01 5 Moderate Calcific Aortic Valve Stenosis (CAVS)
• Study of Nemolizumab for the treatment of adults with systemic sclerosis Pending
  2025-522294-11-00 4 Systemic sclerosis
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS … Pending
  2025-523432-39-01 9 Advanced KRAS G12D-Mutant Solid Tumors
• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3 … Pending
  2025-523674-16-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F … Pending
  2025-523675-39-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A study to test single and multiple doses of MER511 given to adults with Graves’ disease Pending
  2025-523823-23-00 1 Graves’ disease
• DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending
  2025-523895-22-00 4 Non-small cell lung cancer (NSCLC)
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)

Showing 1–24 of 561 trials